Articles From: Camtek Schedules Second Quarter 2013 Results Release and Conference Call for Thursday, August 8, 2013 to Canaccord Financial Inc. Discloses Normal Course Issuer Bid/Buy-Back Programme


MIGDAL HAEMEK, Israel , August 1, 2013 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek Schedules Second Quarter 2013 Results Release and Conference Call for Thursday, August 8, 2013 investment picks
MIGDAL HA'EMEK, Israel , October 30, 2013 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek Schedules Third Quarter 2013 Results Release and Conference Call for Thursday, November 7, 2013 investment picks
2014/2/25
MIGDAL HA'EMEK, Israel , February 25, 2014 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek to Present at the 26th Annual Roth Capital Growth Conference investment picks
MIGDAL HA'EMEK, Israel , January 7, 2014 /PRNewswire/ -- C amtek Ltd.
Sign-up for Camtek to Present at the Annual Needham Growth Conference in New York investment picks
MIGDAL HA'EMEK, Israel , November 12, 2013 /PRNewswire/ -- Camtek Ltd.
Sign-up for Camtek to Present at Upcoming LD Micro & Midtown CAP Summit Events investment picks
2014/1/8
By Al Lewis Asking America's biggest bank to go two full years without committing a federal crime is like expecting Lindsay Lohan not to party.
Sign-up for Can J.P. Morgan really go 2 years without breaking law? investment picks
By Maria LaMagna, MarketWatch Of all the features consumers want in a coffee machine, the ability to make soup probably isn't high on the list.
Sign-up for Can Keurig caffeinate soup sales? investment picks
2013/8/27
By Therese Poletti, MarketWatch SAN FRANCISCO (MarketWatch) -- Investors and pundits are still tossing about names of executives who could lead Microsoft Corp.
Sign-up for Can Microsoft find CEO for a major reboot? investment picks
http://media.marketwire.com/attachments/201308/180456_eHealth_logo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1079188&ProfileId=051205&sourceType=1 MOUNTAIN VIEW, CA --
Sign-up for Can Obamacare Predict Pro Football Winners? -- eHealth Survey Finds Playoff Quarterbacks Are Favorites of Those Impacted by Law investment picks
2014/3/3
PETACH TIKVA, Israel , March 3, 2014 /PRNewswire/ -- Can-Fite BioPharma   Ltd.
Sign-up for Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program investment picks
2013/12/5
Results for CF101 Drug Clinical Trials addressing Rheumatoid Arthritis and Dry Eye Syndrome to be announced by year end 2013 PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite Anticipates Results from Two Clinical Trials investment picks
2013/12/23
PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis investment picks
Company's CF101 was selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier PETACH TIKVA, Israel , Nov.
Sign-up for Can-Fite BioPharma Generates Partnership Interest at Therapeutic Area Partnerships Conference in Boston investment picks
2013/11/5
Non-deal road show in Zurich, Geneva, and Paris PETACH TIKVA, Israel , Nov.
Sign-up for Can-Fite BioPharma to Conduct European Road Show investment picks
2013/12/11
PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite CEO Issues Letter to Shareholders investment picks
http://media.marketwire.com/attachments/201309/65574_canfitelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1053026&ProfileId=051205&sourceType=1 PETACH TIKVA, ISRAEL --
Sign-up for Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com investment picks
2013/12/2
Celebrating Recent Uplisting of Can-Fite's Level II ADR's onto NYSE MKT PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite CEO to Ring Opening Bell at New York Stock Exchange investment picks
2014/2/11
Company's Proprietary Drug CF101 Well-Positioned to Benefit from a Global RA Drug Market Study Forecasted to Generate Revenues of $38.5 bn in 2017 PETACH TIKVA, Israel , Feb.
Sign-up for Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity investment picks
2014/3/10
PETACH TIKVA, Israel , March 10, 2014 /PRNewswire/ --  Can-Fite BioPharma Ltd.
Sign-up for Can-Fite Completes $5 Million Private Placement investment picks
2014/3/31
PETACH TIKVA, Israel , March 31, 2014 /PRNewswire/ --  Can-Fite BioPharma   Ltd.
Sign-up for Can-Fite Files 2013 Annual Report on Form 20-F investment picks
2014/2/25
The patent confers exclusive right for the manufacturing of CF101 in Japan until 2028 and bolsters license agreement that Can-Fite has already signed in Japan PETACH TIKVA, Israel , Feb.
Sign-up for Can-Fite Granted Patent on the Manufacturing of CF101 in Japan investment picks
2014/2/18
PETACH TIKVA, Israel , Feb.
Sign-up for Can-Fite Provides Update on Key Milestones for 2014 investment picks
http://media.marketwire.com/attachments/201308/65368_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1046482&ProfileId=051205&sourceType=1 PETACH TIKVA, ISRAEL --
Sign-up for Can-Fite to Initiate a Phase II Study With CF102 in 130 Patients With Advanced Liver Cancer investment picks
2013/9/3
http://media.marketwire.com/attachments/201309/65574_canfitelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1047616&ProfileId=051205&sourceType=1 PETACH TIKVA, ISRAEL --
Sign-up for Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013 investment picks
2014/2/27
PETACH TIKVA, Israel , Feb.
Sign-up for Can-Fite to Present at the 26th Annual ROTH Capital Conference investment picks
2014/3/25
PETACH TIKVA, Israel , March 25, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd.
Sign-up for Can-Fite to Present at the 9th International Congress of Autoimmunity investment picks
OneMedForum San Francisco 2014 on January 13th Biotech Showcase™ 2014 on January 14th PETACH TIKVA, Israel , Jan.
Sign-up for Can-Fite to Present at Two Upcoming Healthcare Investor Conferences investment picks
Canaccord Financial Inc. Discloses Normal Course Issuer Bid/Buy-Back Programme Canada NewsWire The Company has also entered into a pre-defined plan with a designated broker to allow for the repurchase of its common shares under this normal course issuer bid.
Sign-up for Canaccord Financial Inc. Discloses Normal Course Issuer Bid/Buy-Back Programme investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Camtek Schedules Second Quarter 2013 Results Release and Conference Call for Thursday, August 8, 2013 to Canaccord Financial Inc. Discloses Normal Course Issuer Bid/Buy-Back Programme
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity